首页> 外文期刊>Leukemia Research Reports >The role of the Exon 13 G571S JAK2 mutation in myeloproliferative neoplasms
【24h】

The role of the Exon 13 G571S JAK2 mutation in myeloproliferative neoplasms

机译:Exon 13 G571S JAK2突变在骨髓增生性肿瘤中的作用

获取原文
           

摘要

The exon 14 JAK2 V617F mutation has been well established as a driver mutation in polycythemia vera (PV) and other myeloproliferative neoplasms. JAK2 exon 12 mutations have also been implicated in PV, although patients with these mutations may show isolated erythrocytosis. Recently additional JAK2point mutations have been described―all in regions encoding the pseudokinase domain that regulates the tyrosine kinase activity of JAK2. We present a case of a patient with erythrocytosis and an exon 13 G571S mutation, and discuss the putative role of this mutation in myeloproliferative neoplasms.
机译:外显子14 JAK2 V617F突变已被很好地确定为真性红细胞增多症(PV)和其他骨髓增生性肿瘤中的驱动突变。 JAK2外显子12突变也与PV有关,尽管具有这些突变的患者可能显示出孤立的红细胞增多症。最近,已经描述了其他的JAK2point突变-全部位于编码伪激酶结构域的区域,该区域调节JAK2的酪氨酸激酶活性。我们介绍了一例患者的红细胞增多症和外显子13 G571S突变,并讨论该突变在骨髓增生性肿瘤中的假定作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号